Bio-Rad receives pre-market approval for HIV test from FDA
Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.
Featured Articles
Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study
Biotech company Ligand Pharmaceuticals Inc. reported Tuesday that its partner GlaxoSmithKline received encouraging results in Hepatitis C study.
Leading Expert On U.S. Health Reform Gives His Two Cents
Paul Keckley noted that things may get worse before they get better in the healthcare and lifescience industry in the United States.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
CEO Interview: Michael Moe On GSV Capital, A New Vehicle To Finance Growth Companies
GSV Capital Founder & CEO Michael Moe interviewed by OneMedRadio. GSV raised $50 million in an IPO in May 2011 to invest in emerging technology companies.
Novartis’ NVA237 improves lung function in pulmonary disease patients
Swiss drug maker Novartis said results from a phase three study remarkably improved lung function in a similar way to a rival drug.
Clinical Trials Managed in “The Cloud?”
The fundamental concept of cloud computing dates back to the 1960s, when John McCarthy was quoted as saying “computation may someday be organized as public utility.”
Protected: OneMedRadio: The JOBS Act — Promises and Pitfalls
There is no excerpt because this is a protected post.
Critical Sales and Distribution Considerations for the Buyer, Investor and Seller
For many emerging companies, one of their largest financial investments and most important strategic decisions is their approach to sales and distribution.
CEO Interview: Larry Birch Discusses DataTRAK Collaboration and Patent Suit
After bringing his clinical research software company back from near bankruptcy to steady profitability in 2010, CEO Larry Birch is going on the offensive.